Výsledky vyhledávání - "KARL L. BRUCHHAGE"

Akademický článek

Impact of a mobile application (reminder app) on acute toxicity during radiotherapy of head-and-neck cancer – results of a randomized phase III trial (RAREST-02)

Autor: Dirk Rades, Inga Zwaan, Jon Cacicedo, Karl L. Bruchhage, Samer G. Hakim, Denise Olbrich, Steven E. Schild, Soeren Tvilsted, Stefan Janssen

Publikováno v: BMC Cancer, Vol 22, Iss 1, Pp 1-9 (2022)

Abstract Background Radiotherapy of head-and-neck cancer (SCCHN) is often associated with acute toxicity. In a previous trial, daily reminders by staff members to perform skin care resulted in less dermatitis. This randomized trial investigated wheth

Externí odkaz: https://doaj.org/article/28daba2668bd4fde9445536e81f3148d

Zobrazit plný text záznamu

Plný text ve formátu HTML

A New Prognostic Instrument for Predicting the Probability of Completion of Cisplatin during Chemoradiation for Head and Neck Cancer

Autor: Soror, Dirk Rades, Inga Zwaan, Christian Idel, Ralph Pries, Karl L. Bruchhage, Samer G. Hakim, Nathan Y. Yu, Tamer

Publikováno v: Journal of Personalized Medicine; Volume 13; Issue 7; Pages: 1120

Many head and neck cancer patients assigned to definitive or adjuvant chemoradiation treatment do not complete the concurrent cisplatin dose. We determined corresponding risk factors and developed a prognostic instrument to help identify these patien

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=multidiscipl::53cab869f5be1673caafc6affe9492c6

Zobrazit plný text záznamu

Chemoradiation with Cisplatin vs. Carboplatin for Squamous Cell Carcinoma of the Head and Neck (SCCHN)

Autor: Yu, Dirk Rades, Inga Zwaan, Tamer Soror, Christian Idel, Ralph Pries, Karl L. Bruchhage, Samer G. Hakim, Nathan Y.

Publikováno v: Cancers; Volume 15; Issue 13; Pages: 3278

Cisplatin is the standard for the chemoradiation of squamous cell carcinoma of the head and neck (HNSCC). Many patients cannot receive cisplatin due to impaired renal function. This study investigated carboplatin as an alternative option. In total, 1

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=multidiscipl::2d84545a8de7bce15b79dad797a57998

Zobrazit plný text záznamu

Plný text ve formátu HTML

First Results of Concurrent Chemoradiation with Two Courses of 5 × 25 mg/m2 Cisplatin for Locally Advanced Head and Neck Cancer

Autor: Rades, Inga Zwaan, Tamer Soror, Christian Idel, Ralph Pries, Karl L. Bruchhage, Samer G. Hakim, Nathan Y. Yu, Dirk

Publikováno v: Journal of Personalized Medicine; Volume 13; Issue 6; Pages: 1006

Many patients with squamous cell carcinoma of the head and neck (SCCHN) receive cisplatin-based chemoradiation. Cisplatin 100 mg/m2 every three weeks is toxic and alternative cisplatin regimens are desired. Two courses of 20 mg/m2/day 1–5 (cumulati

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=multidiscipl::d3eeb281f680ce0e86bfd023b2498482

Zobrazit plný text záznamu

Palliative Local Radiotherapy for Advanced Squamous Cell Carcinoma of the Head-and-Neck: Prognostic Factors of Survival

Autor: Karl L Bruchhage, Julika Ribbat-Idel, Christian Idel, Sven Perner, Dirk Rades, Steven E. Schild, Samer G. Hakim, Christian Staackmann

Publikováno v: Anticancer Research. 41:3205-3210

BACKGROUND/AIM A considerable number of patients with advanced head-and-neck cancer (SCCHN) receive palliative radiotherapy. This study aimed to identify prognostic factors for survival to facilitate personalized treatment for these patients. PATIENT

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9213979a395e0f2607a878dd9fb17451
https://doi.org/10.21873/anticanres.15107

Zobrazit plný text záznamu

A New Survival Score for Patients Scheduled for Palliative Irradiation of Locally Advanced Carcinoma of the Head-and-Neck

Autor: Julika Ribbat-Idel, Karl L Bruchhage, Sven Perner, Dirk Rades, Samer G. Hakim, Christian Staackmann, Christian Idel, Steven E. Schild

Publikováno v: Anticancer Research. 41:3055-3058

BACKGROUND/AIM Patients with advanced squamous cell carcinoma of the head-and-neck (SCCHN) may be assigned to palliative irradiation. A survival score was developed for this group to support treatment personalization. PATIENTS AND METHODS Seventy-eig

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::71ff60540d4ea1718d9941ed053abc90
https://doi.org/10.21873/anticanres.15088

Zobrazit plný text záznamu

Accelerated Fractionation With Concomitant Boost vs. Conventional Radio-chemotherapy for Definitive Treatment of Locally Advanced Squamous Cell Carcinoma of the Head-and-Neck (SCCHN)

Autor: Dirk Rades, Steven E. Schild, Carlos A Narvaez, Karl L Bruchhage, Ursula Schroeder, Samer G. Hakim, Stefan Janssen

Publikováno v: Anticancer Research. 41:477-484

Background/aim Patients with unresectable head-and-neck cancer (SCCHN) unable to tolerate radiochemotherapy may receive unconventionally fractionated radiotherapy. This retrospective study compared both treatments. Patients and methods Eight patients

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::9741c7e811056842f39573058905f3ad
https://doi.org/10.21873/anticanres.14798

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání